Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their pharmacovigilance obligations. It is critical to detect safety signals as soon as possible to affect appropriate measures and protect patient safety. Medical literature is an important source of information and contributes to the detection of safety signals. The success of published literature surveillance is measured by precision and sensitivity.

Explore related content and topics